Extracorporeal shock wave lithotripters
This article was originally published in The Gray Sheet
Executive SummaryDraft guidance to be used by FDA in support of downclassification to Class II of devices for use in fragmentation of kidney and ureteral calculi is released on the agency website Oct. 28. The guidance largely follows the suggestions of FDA's Gastroenterology and Urology Devices Panel, which recommended that only 20 patients at two sites be evaluated in clinical studies of the devices following downclassification ("The Gray Sheet" Aug. 3, p. 8)
You may also be interested in...
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.